News

Filter

Current filters:

tivozanibDiabetes

1 to 9 of 97182 results

Portola’s andexanet alfa reverses Eliquis anticoagulant effect

17-12-2014

A Phase III clinical trial has found that Portola Pharmaceuticals' (Nasdaq: PTLA) andexanet alfa reverses…

andexanet alfaBristol-Myers SquibbCardio-vascularEliquisPfizerPharmaceuticalPortola PharmaceuticalsResearch

Strong top-line results for Poxel’s antidiabetic agent imeglimin

17-12-2014

France-based drug developer Poxel says that imeglimin, a novel compound in development to treat type…

DiabetesHealthimegliminMerck SeronoPharmaceuticalPoxelResearch

KCR acquires project portfolio from Ukraine’s CRO AXIS

KCR acquires project portfolio from Ukraine’s CRO AXIS

17-12-2014

KCR, a Poland-based contract research organization (CRO), has recently acquired the whole portfolio of…

AXIS GroupKCRMergers & AcquisitionsPharmaceuticalResearchUkraine

Ipsen appoints François Garnier as executive vice president, general counsel

Ipsen appoints François Garnier as executive vice president, general counsel

17-12-2014

French drugmaker Ipsen has appointed François Garnier as executive vice president, general counsel of…

BoardroomFranceIpsenIpsen GroupPharmaceutical

New guidance provides optimism for securing life sciences patents in USA

New guidance provides optimism for securing life sciences patents in USA

17-12-2014

The US Patent and Trademark Office (USPTO) has released its 2014 Interim Guidance on Patent Subject Matter…

PatentsPharmaceuticalPrometheus LabsUS Patent and Trademark OfficeUSA

FDA approves Ipsen's Somatuline for metastatic gastroentero pancreatic neuroendocrine tumors

FDA approves Ipsen's Somatuline for metastatic gastroentero pancreatic neuroendocrine tumors

17-12-2014

The US Food and Drug Administration has approved Somatuline Depot (lanreotide) injection 120mg, manufactured…

IpsenOncologyPharmaceuticalRegulationSomatulineUSA

Top 30 Pharmas spent $112 billion on R&D in 2013; report

Top 30 Pharmas spent $112 billion on R&D in 2013; report

17-12-2014

The world’s leading 30 pharmaceutical companies spent a combined $112 billion on research and development…

FinancialGlobalGlobalDataJohnson & JohnsonNovartisPfizerPharmaceuticalPharmaceutical sciencesResearch

1 to 9 of 97182 results

Back to top